Orai3 CRISPR Activation Plasmid (h): sc-403426-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Orai3 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Orai3 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Orai3 CRISPR Activation Plasmid (h) and Orai3 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the ORAI3 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Orai3 CRISPR Activation Plasmid (h) | sc-403426-ACT | 20 µg | $397.00 |
ORAI3 encodes Orai3, a plasma membrane Ca2+ release–activated Ca2+ (CRAC) channel subunit that contributes to store-operated calcium entry (SOCE) following endoplasmic reticulum Ca2+ depletion. By shaping cytosolic Ca2+ dynamics, Orai3 influences downstream Ca2+-dependent signaling programs, including NFAT-driven transcription, cell-cycle progression, and stimulus-coupled secretion. ORAI3 function intersects with STIM proteins and other ORAI family members to tune channel assembly and ion selectivity, thereby modulating cellular excitability and stress responses. Dysregulated ORAI3 expression or SOCE remodeling has been linked in the literature to altered proliferative signaling, oxidative stress handling, and phenotypes relevant to cancer biology and immune cell function.
Orai3 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous ORAI3 expression without altering the underlying DNA sequence.
Orai3 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the ORAI3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the ORAI3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Orai3 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native ORAI3 locus and enabling the study of Orai3-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Orai3 pathway restoration in tumor cells with silenced or reduced ORAI3 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.